{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T05:14:04Z","timestamp":1793250844026,"version":"4.5.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016239","name":"University of Occupational and Environmental Health Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016239","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Rheumatology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.berh.2025.102101","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T22:41:47Z","timestamp":1759876907000},"page":"102101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Novel therapies in treatments of SLE"],"prefix":"10.1016","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2025.102101_bib1","series-title":"Harrison's principles of internal medicine","first-page":"2736e51","article-title":"Systemic lupus erythematosus","author":"Hahn","year":"2022"},{"issue":"4","key":"10.1016\/j.berh.2025.102101_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2022.101814","article-title":"Systemic lupus erythematosus","volume":"36","author":"Tanaka","year":"2022","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.berh.2025.102101_bib3","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"European League against Rheumatism\/American College of Rheumatology Classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102101_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000590","article-title":"Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies","volume":"8","author":"Ugarte-Gil","year":"2021","journal-title":"Lupus Sci Med"},{"issue":"9","key":"10.1016\/j.berh.2025.102101_bib5","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1093\/rheumatology\/kez584","article-title":"Risk factors of damage in early diagnosed systemic lupus erythematosus: results of the Italian multicentre Early Lupus Project inception cohort","volume":"59","author":"Piga","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.berh.2025.102101_bib6","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2025.102101_bib7","doi-asserted-by":"crossref","DOI":"10.1172\/JCI144918","article-title":"Bite of the wolf: innate immune responses propagate autoimmunity in lupus","volume":"131","author":"Gupta","year":"2021","journal-title":"J Clin Investig"},{"key":"10.1016\/j.berh.2025.102101_bib8","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41590-020-0677-6","article-title":"Autoimmunity and organ damage in systemic lupus erythematosus","volume":"21","author":"Tsokos","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.berh.2025.102101_bib9","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nm.2752","article-title":"Taming lupus-a new understanding of pathogenesis is leading to clinical advances","volume":"18","author":"Liu","year":"2012","journal-title":"Nat Med"},{"issue":"7909","key":"10.1016\/j.berh.2025.102101_bib10","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41586-022-04642-z","article-title":"TLR7 gain-of-function genetic variation causes human lupus","volume":"605","author":"Brown","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.berh.2025.102101_bib11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/1756-185X.13817","article-title":"State-of-the-art treatment of systemic lupus erythematosus","volume":"23","author":"Tanaka","year":"2020","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.berh.2025.102101_bib12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/mr\/roac007","article-title":"Rituximab in the real-world treatment of lupus nephritis: a retrospective cohort study in Japan","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"issue":"10","key":"10.1016\/j.berh.2025.102101_bib13","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.2215\/CJN.01070118","article-title":"Peripheral blood B cell depletion after Rituximab and complete response in lupus nephritis","volume":"13","author":"Gomez Mendez","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6505","key":"10.1016\/j.berh.2025.102101_bib14","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1126\/science.abb8008","article-title":"Binding mechanisms of therapeutic antibodies to human CD20","volume":"369","author":"Kumar","year":"2020","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.berh.2025.102101_bib15","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2025.102101_bib16","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/art.10856","article-title":"BG9588 Lupus Nephritis Trial Group. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis","volume":"48","author":"Boumpas","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2025.102101_bib17","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","article-title":"Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus","volume":"60","author":"Furie","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.berh.2025.102101_bib18","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","article-title":"Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Navarra","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.berh.2025.102101_bib19","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1093\/rheumatology\/keab953","article-title":"Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus","volume":"61","author":"Miyazaki","year":"2022","journal-title":"Rheumatology"},{"key":"10.1016\/j.berh.2025.102101_bib20","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.berh.2025.102101_bib21","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/art.43059","article-title":"Safety and efficacy of ianalumab in patients with Sj\u00f6gren's disease: 52-week results from a randomized, Placebo-Controlled, phase 2b dose-ranging study","volume":"77","author":"D\u00f6rner","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2025.102101_bib22","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/ard-2023-224854","article-title":"Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial","volume":"83","author":"Wu","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.berh.2025.102101_bib23","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1056\/NEJMoa2118025","article-title":"Trial of Anti-BDCA2 antibody litifilimab for systemic lupus erythematosus","volume":"387","author":"Furie","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.berh.2025.102101_bib24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa2118024","article-title":"Trial of Anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus","volume":"387","author":"Werth","year":"2022","journal-title":"N Engl J Med"},{"issue":"10289","key":"10.1016\/j.berh.2025.102101_bib25","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.berh.2025.102101_bib26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/art.42657","article-title":"Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial","volume":"76","author":"Saxena","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2025.102101_bib27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"11","key":"10.1016\/j.berh.2025.102101_bib28","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/art.41032","article-title":"Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial","volume":"71","author":"Fleischmann","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"16","key":"10.1016\/j.berh.2025.102101_bib29","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of upadacitinib or abatacept in rheumatoid arthritis","volume":"383","author":"Rubbert-Roth","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.berh.2025.102101_bib30","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/art.42926","article-title":"Efficacy and safety of upadacitinib or elsubrutinib alone or in combination for patients with systemic lupus erythematosus: a phase 2 randomized controlled trial","volume":"76","author":"Merrill","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"10381","key":"10.1016\/j.berh.2025.102101_bib31","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)","volume":"401","author":"Petri","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.berh.2025.102101_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-005072","article-title":"Fine-tuning SLE treatment: the potential of selective TYK2 inhibition","volume":"10","author":"Satoh-Kanda","year":"2024","journal-title":"RMD Open"},{"issue":"2","key":"10.1016\/j.berh.2025.102101_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003991","article-title":"Modifying T cell phenotypes using TYK2 inhibitor and its implications for the treatment of systemic lupus erythematosus","volume":"10","author":"Satoh-Kanda","year":"2024","journal-title":"RMD Open"},{"issue":"502","key":"10.1016\/j.berh.2025.102101_bib34","doi-asserted-by":"crossref","first-page":"eaaw1736","DOI":"10.1126\/scitranslmed.aaw1736","article-title":"Autoimmune pathways in mice and humans are blocked by pharmacological stabilization of the TYK2 pseudokinase domain","volume":"11","author":"Burke","year":"2019","journal-title":"Sci Transl Med"},{"issue":"14","key":"10.1016\/j.berh.2025.102101_bib35","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of Selective Tyrosine Kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.berh.2025.102101_bib36","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2025.102101_bib37","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/S2665-9913(24)00246-7","article-title":"Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial","volume":"7","author":"Askanase","year":"2025","journal-title":"Lancet Rheumatol"},{"issue":"2","key":"10.1016\/j.berh.2025.102101_bib38","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nbt0202-143","article-title":"Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB","volume":"20","author":"Maus","year":"2002","journal-title":"Nat Biotechnol"},{"issue":"11","key":"10.1016\/j.berh.2025.102101_bib39","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1038\/nm1310","article-title":"Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer","volume":"11","author":"Rapoport","year":"2005","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.berh.2025.102101_bib40","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.immuni.2013.07.002","article-title":"Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology","volume":"39","author":"Kalos","year":"2013","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.berh.2025.102101_bib41","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMc2107725","article-title":"CD19-Targeted CAR T cells in refractory systemic lupus erythematosus","volume":"385","author":"Mougiakakos","year":"2021","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.berh.2025.102101_bib42","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"10416","key":"10.1016\/j.berh.2025.102101_bib43","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.berh.2025.102101_bib44","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell therapy in autoimmune disease - a case series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.berh.2025.102101_bib45","article-title":"Safety and preliminary efficacy of CD19 CAR T-cell treatment in rheumatic disease \u2013 data from the phase I\/II CASTLE basket study [abstract]","author":"Hagen","year":"2025","journal-title":"EULAR"},{"issue":"8","key":"10.1016\/j.berh.2025.102101_bib46","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/14712598.2024.2384086","article-title":"Looking ahead to CD3, T-cell engager bispecific antibodies for hematological malignancies","volume":"24","author":"Reed","year":"2024","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.berh.2025.102101_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.copbio.2022.102799","article-title":"Considerations for design, manufacture, and delivery for effective and safe T-cell engager therapies","volume":"78","author":"Arvedson","year":"2022","journal-title":"Curr Opin Biotechnol"},{"issue":"2","key":"10.1016\/j.berh.2025.102101_bib48","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41584-024-01210-9","article-title":"Opportunities and limitations of B cell depletion approaches in SLE","volume":"21","author":"Stockfelt","year":"2025","journal-title":"Nat Rev Rheumatol"}],"container-title":["Best Practice & Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694225000695?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694225000695?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T17:11:58Z","timestamp":1765386718000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694225000695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S1521694225000695"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2025.102101","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel therapies in treatments of SLE","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2025.102101","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102101"}}